Results 21 to 30 of about 59,490 (287)

Escherichia coli-derived virus-like particles in vaccine development

npj Vaccines, 2017
Recombinant virus-like particle-based vaccines are composed of viral structural proteins and mimic authentic native viruses but are devoid of viral genetic materials. They are the active components in highly safe and effective vaccines for the prevention
Xiaofen Huang, Xin Wang, Jun Zhang, Ningshao Xia, Qinjian Zhao   +4 more
doaj   +1 more source

Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1

Frontiers in Immunology, 2018
It is acknowledged that vaccines remain the best hope for eliminating the HIV-1 epidemic. However, the failure to produce effective vaccine immunogens and the inability of conventional delivery strategies to elicit the desired immune responses remains a ...
Yong Gao, Chanuka Wijewardhana, Jamie F. S. Mann   +2 more
doaj   +1 more source

Exosomes-based particles as inhalable COVID-19 vaccines

Biomedical Technology, 2023
Coronavirus disease 2019 (COVID-19), a severely spreading pandemic, has dramatically brought physiological and economical burdens to people. Although the injectable vaccines have some achievements for coronavirus defense, they still generate accompanied ...
Lu Fan, Li Wang, Xiaoju Wang, Hongbo Zhang   +3 more
doaj   +1 more source

One-way trip: Influenza virus' adaptation to gallinaceous poultry may limit its pandemic potential [PDF]

, 2014
We hypothesise that some influenza virus adaptations to poultry may explain why the barrier for human-to-human transmission is not easily overcome once the virus has crossed from wild birds to chickens.
Alexander, Baigent, Banks, Banks, Belser, Blumenkrantz, Bosch, Brass, Bullough, Butt, Castrucci, Cauldwell, Chan, Chen, Chen, Cheng, Chutinimitkul, Cohen, Connor, Costa, Cotter, Cowling, Cox, De Jong, Dorigatti, DuBois, Elderfield, England, Everitt, Gabbard, Galloway, Gambaryan, Gambaryan, Gao, Garten, Handel, Harvey, Hatta, Hay, Herfst, Hoffmann, Imai, Jia, Karron, Keleta, Killingley, Koerner, Koopmans, Krenn, Kuchipudi, Li, Li, Lin, Lin, Linster, Luke, Maines, Matrosovich, Matrosovich, Matrosovich, Matrosovich, Matsuoka, Munier, Neumann, O'Donnell, Pappas, Peiris, Perdue, Reed, Roberts, Robinson, Roche, Rogers, Rott, Russell, Russell, Schrauwen, Shelton, Shi, Skehel, Smeenk, Sorrell, Sorrell, Steinhauer, Stevens, Suguitan, Sun, Tellier, Tharakaraman, Thoennes, Tumpey, Vines, Wan, Wang, Washington, Webster, Wei, Xiong, Yen, Zhang, Zhou, Zhou   +101 more
core   +2 more sources

The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference

Expert Review of Vaccines, 2019
Virus-like particles (VLPs) and nano-particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines.
Paul Engeroff, Martin F. Bachmann
doaj   +1 more source

Amino-functionalized poly(l-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development [PDF]

, 2015
Background: Poly(L-lactide) (PLLA) is a biodegradable polymer currently used in many biomedical applications, including the production of resorbable surgical devices, porous scaffolds for tissue engineering, nanoparticles and microparticles for the ...
Accardi, Luisa, Ammendolia, Maria Grazia, Casini, Gabriele, D'ILARIO, LUCIO, Di Bonito, Paola, FRANCOLINI, IOLANDA, MARTINELLI, Andrea, Petrone, Linda, PIOZZI, Antonella   +8 more
core   +2 more sources

Virus-like particles in vaccine development

Expert Review of Vaccines, 2010
Virus-like particles (VLPs) are multiprotein structures that mimic the organization and conformation of authentic native viruses but lack the viral genome, potentially yielding safer and cheaper vaccine candidates. A handful of prophylactic VLP-based vaccines is currently commercialized worldwide: GlaxoSmithKline's Engerix (hepatitis B virus) and ...
António, Roldão, Maria Candida M, Mellado, Leda R, Castilho, Manuel J T, Carrondo, Paula M, Alves   +4 more
openaire   +2 more sources

Plant-derived virus-like particles as vaccines [PDF]

Human Vaccines & Immunotherapeutics, 2013
Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that mimic the native architecture of viruses but lack the viral genome. VLPs have emerged as a premier vaccine platform due to their advantages in safety, immunogenicity, and manufacturing.
Qiang, Chen, Huafang, Lai
openaire   +2 more sources

Next generation designer virus-like particle vaccines for dengue

Expert Review of Vaccines, 2019
Introduction: A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection ...
Rahul Shukla, Viswanathan Ramasamy, Ravi Kant Rajpoot, Upasana Arora, Ankur Poddar, Richa Ahuja, Hemalatha Beesetti, Sathyamangalam Swaminathan, Navin Khanna   +8 more
doaj   +1 more source

Evaluation of DNA-Launched Virus-Like Particle Vaccines in an Immune Competent Mouse Model of Chikungunya Virus Infection

Vaccines, 2021
Chikungunya virus (CHIKV) infection can result in chronic and debilitating arthralgia affecting humans in tropical and subtropical regions around the world, yet there are no licensed vaccines to prevent infection.
Jonathan O. Rayner, Jin Hyun Kim, Rosemary W. Roberts, Raphael Ryan Wood, Brian Fouty, Victor Solodushko   +5 more
doaj   +1 more source